Ocugen, Inc.
1.5000-0.02 (-1.32%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · OCGN · USD
Key Stats
Market Cap
468.46MP/E (TTM)
-Basic EPS (TTM)
-0.19Dividend Yield
0%Recent Filings
8-K
Ocugen licenses OCU400 to Korea
Ocugen inked an exclusive license deal with Kwangdong Pharmaceutical on September 11, 2025, handing over rights to develop, commercialize, and sell its OCU400 gene therapy for retinitis pigmentosa in South Korea. The pact nets Ocugen $1 million upfront, up to $6.5 million in regulatory milestones, $1.5 million per $15 million in sales milestones, and a 25% royalty on net sales, while Ocugen handles manufacturing. This bolsters Ocugen's global footprint for OCU400 amid ongoing trials. Yet risks loom if regulatory approvals falter.
8-K
Ocugen commits $5M to Carisma merger
Ocugen locked in a $5.0 million subscription agreement with Carisma on August 29, 2025, to buy shares in a private placement tied to the pending merger of its OrthoCellix subsidiary. This investment forms part of a broader $25.0 million concurrent raise, bolstering the combined entity's resources for NeoCart development. Yet risks loom large. Closing hinges on customary conditions and approvals.
8-K
Ocugen raises $20M via stock offering
Ocugen, Inc. announced a $20 million registered direct offering on August 8, 2025, issuing 20 million shares of common stock and warrants for another 20 million at $1.00 per share to Janus Henderson Investors, with warrants exercisable at $1.50 expiring in two years. Gross proceeds will fund biotech operations, while the investor's 90-day lock-up curbs immediate selling pressure. Yet dilution hits existing shareholders hard. This bolsters Ocugen's cash runway.
10-Q
Q2 FY2025 results
Ocugen posted collaborative arrangement revenue of $1.4M in Q2 FY2025 ended June 30, 2025, up 20% y/y from $1.1M, while YTD revenue climbed 32% y/y to $2.9M, reflecting steady progress in co-development efforts with CanSinoBIO. Operating expenses dipped 9% y/y to $15.2M, trimming the operating loss to $13.8M from $15.4M, though YTD operating loss widened slightly to $28.3M from $27.7M amid higher R&D personnel costs. Diluted EPS improved to $(0.05) from $(0.06) y/y, aligning with 292M weighted shares and no material anti-dilution effects noted. Cash burn intensified, with operating cash use at $30.1M YTD versus $20.5M last year, leaving $27.0M in cash against $28.0M long-term debt (Avenue term loan at prime +4.25%, due 2028, and EB-5 notes at 4%, due through 2029); free cash flow not disclosed in the 10-Q. On June 22, 2025, Ocugen announced a planned merger of its NeoCart regenerative cell therapy assets into Carisma Therapeutics, expecting Q4 close with $25M concurrent financing (Ocugen investing at least $5M) for majority ownership and continued consolidation. Merger delays could disrupt operations. Regulatory hurdles in gene therapy approvals pose ongoing risks.
8-K
Ocugen advances key trials, secures Korea deal
Ocugen kicked off dosing in the Phase 2/3 GARDian3 trial for OCU410ST targeting Stargardt disease, building on Phase 1 data showing 48% slower lesion growth and 9-letter visual acuity gains. The OCU400 Phase 3 trial for retinitis pigmentosa advances toward 2026 BLA filing, while a Korean licensing deal promises up to $11 million in upfront and milestones plus 25% royalties. Cash dipped to $27.3 million, funding operations into Q1 2026. Reverse merger with OrthoCellix spins off NeoCart to sharpen focus on gene therapies.
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
LCTX
Lineage Cell Therapeutics, Inc.
1.71-0.02
LEGN
Legend Biotech Corporation
32.13-0.44
NGNE
Neurogene Inc.
32.67+1.65
OCS
Oculis Holding AG
21.55+0.55
OGEN
Oragenics Inc.
1.29-0.01
PGEN
Precigen, Inc.
4.01-0.05
REGN
Regeneron Pharmaceuticals, Inc.
652.91-1.57
RGNX
REGENXBIO Inc.
12.84-0.32
VXRT
Vaxart, Inc. - Common Stock
0.35+0.00